Your session is about to expire
← Back to Search
Other
RP-G28 administered in the fasted state for Lactose Intolerance (RP Trial)
Phase 1
Waitlist Available
Research Sponsored by Ritter Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2, 3, 2 and 1 days pretreatment; 1 - 13 days post-treatment
Awards & highlights
RP Trial Summary
Randomized, open-label, 2-period, 2-sequence, crossover study to evaluate the effect of a standard meal on the pharmacokinetic (PK) profile of orally administered RP-G28.
RP Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2, 3, 2 and 1 days pretreatment; 1 - 13 days post-treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2, 3, 2 and 1 days pretreatment; 1 - 13 days post-treatment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Area under the plasma concentration-time curve from time 0 extrapolated to infinity
Secondary outcome measures
Adverse events
Hematology
Serum chemistry
+1 moreRP Trial Design
2Treatment groups
Experimental Treatment
Group I: RP-G28 administered in the fed stateExperimental Treatment1 Intervention
RP-G28, 15 g dissolved in water, administered immediately following the consumption of a standard non-dairy meal
Group II: RP-G28 administered in the fasted stateExperimental Treatment1 Intervention
RP-G28, 15 g dissolved in water, administered in the fasted state
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RP-G28
2018
Completed Phase 3
~950
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Ritter Pharmaceuticals, Inc.Lead Sponsor
3 Previous Clinical Trials
995 Total Patients Enrolled
3 Trials studying Lactose Intolerance
995 Patients Enrolled for Lactose Intolerance
Paul G Pearson, PhDStudy DirectorRitter Pharmaceuticals
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger